Scibase Holding
SciBase Holding AB is a Swedish medical technology group focused on dermatology diagnostics and early detection of skin disease. The company develops and commercializes Nevisense, a point-of-care platform that combines electrical impedance spectroscopy and AI to support clinicians in assessing suspicious skin lesions and related skin-barrier applications.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenuePoint-of-care instruments and systems used to assess skin lesions and skin-barrier conditions.
Single-use components required to run the Nevisense diagnostic workflow.
Algorithmic and software elements that support diagnostic interpretation.
Commercial and development-related activities tied to partners and market access.
Customers
SciBase sells primarily to dermatologists, skin cancer clinics, and other clinicians who evaluate suspicious lesions and need objective support in diagnosis. The company also works with research and development partners for new applications in dermatology and skin-barrier assessment. Demand is driven by clinical accuracy, workflow fit, and reimbursement or guideline adoption.
Buy Nevisense to support evaluation of suspicious skin lesions and improve diagnostic confidence.
Use the platform in workflows focused on melanoma and nonmelanoma skin cancer detection.
Work with SciBase on new indications such as atopic dermatitis and skin-barrier applications.
Adopt the device where point-of-care dermatology diagnostics can fit existing clinical pathways.
Strategy
SciBase’s strategy is centered on expanding clinical adoption of Nevisense and extending the platform into additional dermatology and skin-barrier indications. The company also emphasizes regulatory approvals, reimbursement access, and partnerships that can broaden market reach and support commercialization.
The platform needs wider adoption to scale beyond niche use and support recurring demand.
New clinical uses can increase the addressable market and improve platform relevance.
Clinical adoption is easier when the method is recognized in reimbursement systems and guidelines.
Disposable electrodes and components must be available reliably for clinical use and scaling.
Geography
SciBase is headquartered in Stockholm and operates through a Swedish parent company with subsidiaries in the United States and Germany. The business is international in scope, with commercialization tied to regulated markets such as the U.S., EU, and Australia, and with foreign-currency exposure mainly in EUR and, over time, USD.
Risks
SciBase faces commercialization risk because its products depend on regulatory approval, reimbursement, and clinician adoption in a specialized medical market. The company is also exposed to foreign-exchange volatility, supply-chain disruption, and dependence on key personnel and external partners. As a medical technology business, product performance, quality, and compliance are central to both market access and long-term credibility.
- Commercialization and market adoption riskImpact: HighLikelihood: High
Revenue depends on clinicians adopting Nevisense and on successful launches of new applications.
Exposure: Nevisense and Nevisense Go commercialization
- Reimbursement and guideline riskImpact: HighLikelihood: High
Without reimbursement or clinical guideline inclusion, adoption can remain limited.
Exposure: Melanoma and skin-barrier indications
- Supply-chain and component availability riskImpact: HighLikelihood: High
Electronic components and supplies are needed to manufacture and deliver devices and electrodes.
Exposure: Manufacturing and customer deliveries
- Foreign exchange riskImpact: MediumLikelihood: Medium
The group reports in SEK but has exposure to EUR and future USD cash flows and balances.
Exposure: EUR and USD transaction/translation exposure
- Key-person dependenceImpact: MediumLikelihood: Medium
The company relies on experienced personnel with product, partner, and market knowledge.
Exposure
Accounting
Judgemental itemsForeign subsidiaries are translated into SEK, and exchange-rate movements flow through OCI and earnings.
Impact: Affects reported equity, profit, and comparability across periods
Lease liabilities and right-of-use assets affect balance sheet presentation and expense timing.
Impact: Changes leverage metrics and operating expense profile
The parent company carries shares in subsidiaries that may require impairment testing.
Impact: Can materially affect parent-company equity and profit
A medtech company in commercialization phase must judge how to treat development and launch-related spending.
Impact: Affects operating loss timing and period-to-period comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Bactiguard Holding
BACTI-B · Health Care
Bactiguard Holding AB is a global MedTech company based in Stockholm, Sweden, specializing in the development of biocompatible technology to prevent infections associated with medical devices.
Senzime
SEZI · Health Care
Senzime is a global medical technology company specializing in algorithm-based patient monitoring systems aimed at reducing anesthesia-related complications.
Essity B
ESSITY-B · Consumer Staples
Essity Aktiebolag (publ) is a global hygiene and health company that develops, produces, and sells personal care and tissue products.
Spectral AI, Inc.
MDAIW · Surgical & Medical Instruments & Apparatus
CellaVision
CEVI · Health Care
CellaVision is a global medical technology company specializing in the development and sale of advanced solutions for the routine analysis of blood and other body fluids.
Oculis Holding AG
OCS · Pharmaceutical Preparations
Oculis Holding AG is a Switzerland-based biopharmaceutical company focused on therapies for neuro-ophthalmology and ophthalmology.
Last updated: 24/09/2026